- Home
- ONC
as 08-22-2025 4:00pm EST
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
| Founded: | 2010 | Country: | Switzerland |
| Employees: | N/A | City: | BASEL |
| Market Cap: | 37.2B | IPO Year: | N/A |
| Target Price: | $335.78 | AVG Volume (30 days): | 410.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $170.99 - $330.63 | Next Earning Date: | 08-06-2025 |
| Revenue: | $4,562,002,000 | Revenue Growth: | 47.33% |
| Revenue Growth (this year): | 865.19% | Revenue Growth (next year): | 21.12% |
Latest BeiGene Ltd. American Depositary Shares News
ONC Breaking Stock News: Dive into ONC Ticker-Specific Updates for Smart Investing
Simply Wall St.
20 hours ago
BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)
Business Wire
2 days ago
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
Investor's Business Daily
8 days ago
This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth
Investor's Business Daily
8 days ago
This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine
Business Wire
2 months ago
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
Business Wire
2 months ago
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
Simply Wall St.
2 months ago
Exploring US High Growth Tech Stocks To Watch In June 2025
Business Wire
2 months ago
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
Compare ONC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONC BeiGene Ltd. American Depositary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.